Three options: check whether the exclusion applies to all indications or only obesity, request a formulary exception based on the CV or OSA indication if applicable, or look at compounded GLP-1 options through telehealth
I hope your physician has told you that
doi:10.3390/cells9030740 178
Learn More Patricia Hernandez, RN Chris Logan, NP Chris Logan is a San Antonio native who embraces new ideas and evidence-based interventions that enhance patient care
The question that arises is no longer, "Does it work? But, "Who owns the next generation mechanism? Were likely entering a phase where: Large-cap pharma consolidates metabolic platforms Mid-cap biotech becomes an acquisition target (mechanism-driven) Valuations increasingly reflect mechanism optionality, not single indications And importantly: The winners may not be the first GLP-1 players But those building next-gen metabolic architectures Bottom line: If GLP-1 were the opening trade, multi-pathway metabolic drugs may represent the full cycle
Support from caregivers can help children build language skills